Ioflubenzamide I-131 (also known as 131-I-MIP-1145) is a radiolabeled iodobenzamide derivative developed by Molecular Insight Pharmaceuticals, Inc for metastatic melanoma treatment. The benzamide moiety of Ioflubenzamide I-131 binds to melanin, selectively delivering a cytotoxic dose of gamma and beta radiation to melanin-expressing tumor cells. In human melanoma xenografts, Ioflubenzamide I-131 exhibited diffuse tissue distribution and washout from all tissues except melanin-expressing tumors. The administration of Ioflubenzamide I-131 at 25 MBq in single or multiple doses significantly reduced SK-MEL-3 tumor growth, with multiple doses resulting in tumor regression and durable response for over 125 days. Unfortunately Phase I clinical trial was terminated by unknown reason.